MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells

Experimental Cell Research

Volumn 338, Issue 2, 2015, Pages 232-238

  Wu, Jing ^a   Yin, Li ^a   Jiang, Ning ^a   Guo, Wen Jie ^a   Gu, Jia Jia ^a   Chen, Meng ^a   Xia, You You ^a   Wu, Jian Zhong ^a   Chen, Dan ^a   Wu, Jian Feng ^a   Wang, De Jun ^a   Zong, Dan ^a   Zhang, Nan ^a   Ding, Kai ^a   Huang, Teng ^a   He, Xia ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

ADAM17; Invasion; Migration; MiR 145; Nasopharyngeal carcinoma

Indexed keywords

DISINTEGRIN; MICRORNA 145; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UVOMORULIN; VASCULOTROPIN RECEPTOR; 3' UNTRANSLATED REGION; ADAM PROTEIN; CADHERIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MIRN145 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL LINE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL CYCLE G0 PHASE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; NASOPHARYNX TUMOR; PATHOLOGY; RNA PROCESSING; TUMOR CELL LINE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ADAM PROTEINS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA PROCESSING, POST-TRANSCRIPTIONAL; UP-REGULATION;

EID: 84945448428     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.08.006     Document Type: Article

References (48)

1. Chou J., Lin Y.C., Kim J., You L., Xu Z., He B., Jablons D.M. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30:946-963.
2. Lee A.W., Yau T.K., Wong D.H., Chan E.W., Yeung R.M., Ng W.T., Tong M., Soong I.S., Sze W.M. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1331-1338.
3. Kim Y.S., Kim B.S., Jung S.L., Lee Y.S., Kim M.S., Sun D.I., Yoo E.J., Mun S.K., Yoon S.C., Chung S.M., Kim H.K., Jo S.H., Kang J.H. Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years experience of a single institution in Korea. Cancer Res. Treat. Off. J. Kor. Cancer Assoc. 2008, 40:155-163.
4. Farias T.P., Dias F.L., Lima R.A., Kligerman J., de Sa G.M., Barbosa M.M., Goncalves Jr.F.B. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch. Otolaryngol.-Head Neck Surg. 129 2003, 794-799.
5. Qi X., Li J., Zhou C., Lv C., Tian M. MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett. 2014, 588:3732-3738.
6. Yi C., Wang Q., Wang L., Huang Y., Li L., Liu L., Zhou X., Xie G., Kang T., Wang H., Zeng M., Ma J., Zeng Y., Yun J.P. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012, 31:4421-4433.
7. Fontana L., Pelosi E., Greco P., Racanicchi S., Testa U., Liuzzi F., Croce C.M., Brunetti E., Grignani F., Peschle C. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat. Cell Biol. 2007, 9:775-787.
8. Dixon-McIver A., East P., Mein C.A., Cazier J.B., Molloy G., Chaplin T., Andrew Lister T., Young B.D., Debernardi S. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PloS One 2008, 3:e2141.
9. Navarro A., Gaya A., Martinez A., Urbano-Ispizua A., Pons A., Balague O., Gel B., Abrisqueta P., Lopez-Guillermo A., Artells R., Montserrat E., Monzo M. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008, 111:2825-2832.
10. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., Lee J., Fine H., Chiocca E.A., Lawler S., Purrow B. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
11. Yang Z., He M., Wang K., Sun G., Tang L., Xu Z. Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A. Int. J. Clin. Exp. Pathol. 2014, 7:7563-7570.
12. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 2008, 105:5874-5878.
13. Gusev Y. Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods 2008, 44:61-72.
14. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
15. Gregersen L.H., Jacobsen A.B., Frankel L.B., Wen J., Krogh A., Lund A.H. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PloS One 2010, 5:e8836.
16. Wang Y., Lee C.G. MicroRNA and cancer-focus on apoptosis. J. Cell. Mol. Med. 2009, 13:12-23.
17. Yang X.W., Zhang L.J., Huang X.H., Chen L.Z., Su Q., Zeng W.T., Li W., Wang Q. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2014, 44:551-559.
18. Lu Y., Chopp M., Zheng X., Katakowski M., Buller B., Jiang F. MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol. Rep. 2013, 29:67-72.
19. Doberstein K., Steinmeyer N., Hartmetz A.K., Eberhardt W., Mittelbronn M., Harter P.N., Juengel E., Blaheta R., Pfeilschifter J., Gutwein P. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 2013, 15:218-230.
20. Chiyomaru T., Enokida H., Tatarano S., Kawahara K., Uchida Y., Nishiyama K., Fujimura L., Kikkawa N., Seki N., Nakagawa M. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer 2010, 102:883-891.
21. Spizzo R., Nicoloso M.S., Lupini L., Lu Y., Fogarty J., Rossi S., Zagatti B., Fabbri M., Veronese A., Liu X., Davuluri R., Croce C.M., Mills G., Negrini M., Calin G.A. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Diff. 2010, 17:246-254.
22. Sinnathamby G., Zerfass J., Hafner J., Block P., Nickens Z., Hobeika A., Secord A.A., Lyerly H.K., Morse M.A., Philip R. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin. Exp. Immunol. 2011, 163:324-332.
23. Wu B., Sha L., Wang Y., Xu W., Yu Y., Feng F., Sun C., Xia L. Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas. Oncol. Lett. 2014, 8:2616-2620.
24. Liu Y., Yu C., Qiu Y., Huang D., Zhou X., Zhang X., Tian Y. Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2012, 138:195-202.
25. Shen K., Liang Q., Xu K., Cui D., Jiang L., Yin P., Lu Y., Li Q., Liu J. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem. Pharmacol. 2012, 84:320-330.
26. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Investig. 2007, 117:337-345.
27. Arribas J., Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr. Pharm. Des. 2009, 15:2319-2335.
28. Zhang P., Wu S.K., Wang Y., Fan Z.X., Li C.R., Feng M., Xu P., Wang W.D., Lang J.Y. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective study. Oncol. Lett. 2015, 9:113-118.
29. Franovic A., Robert I., Smith K., Kurban G., Pause A., Gunaratnam L., Lee S. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 2006, 66:8083-8090.
30. Scheller J., Chalaris A., Garbers C., Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011, 32:380-387.
31. Liu L., Li H.X., Lv X.Q. The mechanism and significance of E-cadherin, anti-apoptosis B-cell lymphoma-2 protein and sE-cadherin roles in cancer. J. Biol. Regul. Homeost. Agents 2014, 28:683-691.
32. Lai S.Z., Li W.F., Chen L., Luo W., Chen Y.Y., Liu L.Z., Sun Y., Lin A.H., Liu M.Z., Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:661-668.
33. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., Croce C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101:2999-3004.
34. Sevignani C., Calin G.A., Siracusa L.D., Croce C.M. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm. Genome Off. J. Int. Mamm. Genome Soc. 2006, 17:189-202.
35. Bruce J.P., Liu F.F. MicroRNAs in nasopharyngeal carcinoma. Chin. J. Cancer 2014, 33:539-544.
36. Luo Z., Zhang L., Li Z., Li X., Li G., Yu H., Jiang C., Dai Y., Guo X., Xiang J., Li G. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med. Genomics 2012, 5:3.
37. Luo Z., Dai Y., Zhang L., Jiang C., Li Z., Yang J., McCarthy J.B., She X., Zhang W., Ma J., Xiong W., Wu M., Lu J., Li X., Li X., Xiang J., Li G. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis 2013, 34:415-425.
38. Liu N., Tang L.L., Sun Y., Cui R.X., Wang H.Y., Huang B.J., He Q.M., Jiang W., Ma J. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 2013, 329:181-188.
39. Ostenfeld M.S., Bramsen J.B., Lamy P., Villadsen S.B., Fristrup N., Sorensen K.D., Ulhoi B., Borre M., Kjems J., Dyrskjot L., Orntoft T.F. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010, 29:1073-1084.
40. Koo S., Martin G.S., Schulz K.J., Ronck M., Toussaint L.G. Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 2012, 12:143.
41. Chen Z., Zeng H., Guo Y., Liu P., Pan H., Deng A., Hu J. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J. Exp. Clin. Cancer Res. 2010, 29:151.
42. Xu Q., Liu L.Z., Qian X., Chen Q., Jiang Y., Li D., Lai L., Jiang B.H. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012, 40:761-774.
43. Tokino T., Nakamura Y. The role of p53-target genes in human cancer. Crit. Rev. Oncol./Hematol. 2000, 33:1-6.
44. Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull. Cancer 2004, 91:E70-E76.
45. Ruan L., Li X.H., Wan X.X., Yi H., Li C., Li M.Y., Zhang P.F., Zeng G.Q., Qu J.Q., He Q.Y., Li J.H., Chen Y., Chen Z.C., Xiao Z.Q. Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci. 2011, 9:35.
46. Lee W.Y., Shin D.Y., Kim H.J., Ko Y.H., Kim S., Jeong H.S. Prognostic significance of epithelial-mesenchymal transition of extracapsular spread tumors in lymph node metastases of head and neck cancer. Ann. Surg. Oncol. 2014, 21:1904-1911.
47. Cho W.C., Chow A.S., Au J.S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011, 8:125-131.
48. Li Y.Q., Ren X.Y., He Q.M., Xu Y.F., Tang X.R., Sun Y., Zeng M.S., Kang T.B., Liu N., Ma J. MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. Cell Death Dis. 2015, 6:e1618.